Employees voice concern on the future of their company
In its leader, French business daily Les Echos underlined "heavy divisions within Bayer" about the future of the company’s pharmaceuticals business. President of the work’s council and Vice-President of the group’s Board of Trustees, Ehrard Gipperich, said in a statemet to the German press that "as far as the representatives of the employees was concerned, there was no question of Bayer accepting a minority stake in a combined pharmaceutical company, nor a joint-venture with 50:50 split".
While the Board of Trustees of the Bayer group has an equal representation among its staff and shareholders, Les Echos considers that "declarations such as these risk jeopardising Bayer’s negotiations to find a partner for its pharmaceutical operations".
It seems that President of Bayer, Werner Wenning, was astonished by the press revelations as "all options concerning the future strategy for its pharmaceuticals business had been presented to the Board of Trustees."
Keywords : Bayer Germany Pharmaceuticals Strategy Joint-Venture Merger Board of Trustees
<< Back
